<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00362674</url>
  </required_header>
  <id_info>
    <org_study_id>CLV-304</org_study_id>
    <nct_id>NCT00362674</nct_id>
  </id_info>
  <brief_title>Durability of Antiviral Activity in Chronic HBV Patients Who Showed Complete Response in L-FMAU-301,302 or 303 Trial</brief_title>
  <official_title>An Open-label, Observation Study to Evaluate the Durability of Antiviral Activity in Chronic Hepatitis B Patients Who Showed Complete Response in L-FMAU-301,L-FMAU-302 or L-FMAU-303 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bukwang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bukwang Pharmaceutical</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the durability of antiviral activity in chronic
      hepatitis B patients who showed complete response in L-FMAU-301,L-FMAU-302 or L-FMAU-303
      trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <condition>Hepatitis B</condition>
  <eligibility>
    <study_pop>
      <textblock>
        the patients who completed the previous 301, 302 and 303 studies with clevudine
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patients who have completed L-FMAU-301, L-FMAU-302 or L-FMAU-303.

          2. Patients who have showed complete response (ALT normalization and HBV DNA &lt;4,700
             copies/mL in L-FMAU-301 or L-FMAU-302, in addition, HBeAg seroconverted to anti-HBe at
             the last two visits in L-FMAU-301) after completion of L-FMAU-301 or L-FMAU-302 and
             treated with the clevudine.

          3. Patients who have showed complete response (ALT normalization and HBV DNA &lt;4,700
             copies/mL, in addition HBeAg seroconverted to anti-HBe at the last two visits who
             showed HBeAg positiv at baseline) after completion of L-FMAU-303

          4. Patients who were able to give written informed consent prior to study start and to
             comply with the study requirements.

          5. Patients with bilirubin levels less than 2.0 mg/dL, prothrombin time of less than 1.7
             (INR), and a serum albumin level of at least 3.5 g/dL at the last visit in L-FMAU-301,
             L-FMAU-302 or L-FMAU-303.

        Exclusion Criteria:

          1. Patients who have showed complete response but previously treated with placebo in the
             L-FMAU-301, L-FMAU-302.

          2. Patients who were currently receiving antiviral, immunomodulatory or corticosteroid
             therapy.

          3. Patients previously treated with interferon, lamivudine, lobucavir, famciclovir,
             adefovir or any other investigational nucleoside for HBV infection.

          4. Patients with a history of ascites, variceal hemorrhage or hepatic encephalopathy.

          5. Patients co-infected with HCV, HDV or HIV.

          6. Patients with a liver mass (hemangioma, nodule), biliary diseases except asymptomatic
             GB stone during the L-FMAU-301, L-FMAU-302 or L-FMAU-303.

          7. Patients who were pregnant or breast-feeding.

          8. Patients with a significant gastrointestinal, renal, hepatic (decompensated), biliary
             diseases except asymptomatic GB stone, bronchopulmonary, neurological, cardiovascular,
             oncologic or allergic disease. The patients with a benign tumor were excluded if
             judged by an investigator that the continuation of study would be interfered by benign
             tumor.

          9. Patients who were not suitable to the study if judged by an investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Hyo-suk Lee, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Keimyumg University Dongsan Medical Center</name>
      <address>
        <city>Jung-gu,</city>
        <state>Daegu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Guro-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mercy's Hospital</name>
      <address>
        <city>Bupyoung-dong, Bupyoung-gu</city>
        <state>Incheon</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Sinhung-dong, Jung-gu</city>
        <state>Incheon</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonkwang University Hospital</name>
      <address>
        <city>Iksan-City</city>
        <state>Jeonbuk</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju-city</city>
        <state>Jeonbuk</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-Gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Ilsan-gu</city>
        <state>Kyounggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Holly Family Mary's Hospital</name>
      <address>
        <city>Pucheon</city>
        <state>Kyounggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pochon CHA University Hospital</name>
      <address>
        <city>Seongnam-gu</city>
        <state>Kyounggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <state>Namdong-Gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nowon Eulji Hospital</name>
      <address>
        <city>Hagye 1-dong</city>
        <state>Nowon-gu, Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Ami-dong, Seo-gu</city>
        <state>Pusan</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosin Medical Center</name>
      <address>
        <city>Amnam-dong, Seo-gu</city>
        <state>Pusan</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Anam-dong, Sungbuk-ku</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangnam Sacred Heart Hospital</name>
      <address>
        <city>Daelim-dong, Yongdeungpo-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yongdong Severance Hospital</name>
      <address>
        <city>Dogok-dong, Kangnam-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea Cancer Center Hospital</name>
      <address>
        <city>Gongneung-dong, Nowon-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Ilwon-dong, Songpa-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Paik Hospital</name>
      <address>
        <city>Jeo-dong</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ehwa Womans University Mokdong Hospital</name>
      <address>
        <city>Mok-dong, Yangcheon-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Asan Medical Center</name>
      <address>
        <city>Pungnap-dong, Kangnam-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Pyoung-dong, Chongro-gu,</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Shinchon- dong, Seodaemun-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Ji-dong,, Paldal-gu</city>
        <state>Suwon</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daemyoung-dong, Nam-gu</city>
        <state>Taegu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Yungdungpo-Gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2006</study_first_submitted>
  <study_first_submitted_qc>August 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2006</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <name_title>Hun Jun Jang</name_title>
    <organization>Bukwang Pharm.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

